Sign up
Quantellect · Analysts · Analyst Profile
Analyst Score Rank#69 of 589

Silvan Tuerkcan

JMP Securities · Equity Research Analyst
EstablishedRating since 2022No new ratings since Nov 2025

Analyst rating accuracy & track record

Silvan Tuerkcan is an equity research analyst at JMP Securities. Quantellect has scored 57 of their stock calls across 18 companies. Their picks beat their sector 51% of the time over the next 12 months, and their price targets were reached 30% of the time within a year.

Win % vs sector
51%
PT Hit % (12mo)
30%
Avg sector-excess
+4.5%
Scored calls
57
Tickers
18
Tier
Established

Track record

Quantellect has scored 57 of Silvan Tuerkcan's stock calls across 18 companies, dating back to 2022. Their rated stocks beat their own sector 51% of the time over the next 12 months. On a typical call, a Tuerkcan pick returned +4.5% more than its sector over the following year.

Of the scored calls, 57 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
TSHATaysha Gene Therapies Inc
Buy$8.00Nov 2025−23.4%Miss
BNTCBenitec Biopharma Inc.
Buy$22.00Nov 2025−72.5%Miss
FHTXFoghorn Therapeutics Inc
Buy$9.00Oct 2025−78.3%Miss
IDYAIdeaya Biosciences Inc
Buy$45.00Oct 2025+6.4%Miss
IDYAIdeaya Biosciences Inc
Buy$45.00Oct 2025+6.4%Miss
BNTCBenitec Biopharma Inc.
Buy$20.00Sep 2025−57.9%Miss
JSPRJasper Therapeutics Inc
Buy$6.00Sep 2025−99.1%Miss
ACRVAcrivon Therapeutics, Inc. Common Stock
Buy$13.00Sep 2025−22.1%Miss
SLDBSolid Biosciences LLC
Buy$15.00Sep 2025+35.1%Miss
IDYAIdeaya Biosciences Inc
Buy$45.00Sep 2025+34.8%Miss
PHRPhreesia Inc
Buy$34.00Sep 2025−83.7%Miss
IDYAIdeaya Biosciences Inc
Buy$41.00Sep 2025+20.8%Hit
EXELExelixis Inc
Buy$50.00Jul 2025+24.6%Hit
EXELExelixis Inc
Buy$50.00Jul 2025+24.6%Hit
CRSPCrispr Therapeutics AG
Buy$86.00Jun 2025−5.0%Miss
NUVBNuvation Bio Inc
Buy$6.00Jun 2025+177.5%Hit
PRMEPrime Medicine, Inc. Common Stock
Buy$6.00Jun 2025+41.9%Hit
CNTXContext Therapeutics Inc
Buy$4.00Jun 2025+243.7%Miss
NUVBNuvation Bio Inc
Buy$6.00Jun 2025+88.0%Hit
TSHATaysha Gene Therapies Inc
Buy$6.00May 2025+101.9%Hit
FHTXFoghorn Therapeutics Inc
Buy$9.00May 2025−25.4%Miss
BNTCBenitec Biopharma Inc.
Buy$20.00May 2025−26.5%Miss
FHTXFoghorn Therapeutics Inc
Buy$9.00Apr 2025+5.4%Miss
ENGNenGene Therapeutics Inc.
Buy$18.00Apr 2025+66.5%Miss
TSHATaysha Gene Therapies Inc
Buy$5.00Apr 2025+241.0%Hit
Prev1
Go to

Silvan Tuerkcan: analyst track record FAQ

Is Silvan Tuerkcan a good stock analyst?

Yes, by track record. Silvan Tuerkcan ranks number 69 of 589 of the analysts Quantellect scores, with an Analyst Score of 64 out of 100. Past results do not guarantee future ones.

What is Silvan Tuerkcan's win rate?

Silvan Tuerkcan's win rate is 51%. Across 57 scored calls, their rated stocks beat their sector 51% of the time over the next 12 months. On a typical call they returned +4.5% more than the sector.

What stocks and sectors does Silvan Tuerkcan cover?

Silvan Tuerkcan covers 18 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Silvan Tuerkcan's price targets accurate?

Silvan Tuerkcan's price targets are reached within 12 months 30% of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Silvan Tuerkcan's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Silvan Tuerkcan rank among Wall Street analysts?

Silvan Tuerkcan ranks number 69 of 589 by Analyst Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.